{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:14:49Z","timestamp":1790835289861,"version":"4.1.0"},"reference-count":23,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Cystic fibrosis is a genetically determined disease that significantly influences and shortens life. Treatment with CFTR modulators (CFTR-T) is a new hope for patients. It can change the predictive values of a poor prognosis (e.g., exacerbation rate and FEV1 value). The aim of the study was to analyse exacerbation incidence and spirometry data before and after one year (+\/\u2212 2 weeks) of CFTR-T in 85 CF patients at the CF Centre in Pozna\u0144. To our knowledge, this is the first analysis of CFTR-T efficiency in the Central\u2013Eastern Europe population. Methods: We retrospectively analysed the spirometry and exacerbation data of 85 CF adult patients (both men and women), who in the middle of 2022 began treatment with CFTR modulators. Results: The one-year ratio of hospitalisation caused by severe exacerbations lowered from 1.25 to 0.21 per patient per year. We also saw a 66% decline in ambulatory exacerbations. The median FEV1% increased by 9.60% in absolute values and by 460 mL. Even in the group with very severe obstruction (FEV1 &lt; 35%), there was an increase in median FEV1% of 5.9 in absolute values. We also proved the increase in FVC% (median 17.10% in absolute value and 600 mL) in the study group. Conclusions: After one year of treatment, an impressive improvement was observed in two important predictive values of poor prognosis: exacerbation rate and FEV1 values. Further observation is needed to determine how long the improvement will be present and its influence on quality of life and life expectancy.<\/jats:p>","DOI":"10.3390\/jcm13154491","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:16:49Z","timestamp":1722446209000},"page":"4491","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CFTR Modulators Therapy Efficacy in Reducing Cystic Fibrosis (CF) Exacerbation and Improving Selected Spirometry Parameters: A Real-Life Study in a Single-Centre Polish Population"],"prefix":"10.3390","volume":"13","author":[{"given":"Hanna M.","family":"Winiarska","sequence":"first","affiliation":[{"name":"Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Springer","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Wojta\u015b","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-7656","authenticated-orcid":false,"given":"Ewa","family":"Wysocka","sequence":"additional","affiliation":[{"name":"Chair and Department of Laboratory Diagnostics, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szczepan","family":"Cofta","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref_1","first-page":"500","article-title":"CFTR Modulators for the Treatment of Cystic Fibrosis","volume":"39","author":"Pettit","year":"2014","journal-title":"P T"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/thorax.56.10.746","article-title":"Wasting as an independent predictor of mortality in patients with cystic fibrosis","volume":"56","author":"Sharma","year":"2001","journal-title":"Thorax"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcf.2015.01.007","article-title":"Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"14","author":"Waters","year":"2015","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200405-667OC","article-title":"One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis","volume":"171","author":"Ellaffi","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1479972311433575","article-title":"Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis","volume":"9","author":"Sequeiros","year":"2012","journal-title":"Chronic Respir. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ppul.23217","article-title":"Risk factors for lung function decline in a large cohort of young cystic fibrosis patients","volume":"50","author":"Cogen","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2011-200953","article-title":"Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study","volume":"67","author":"Whitehead","year":"2012","journal-title":"Thorax"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ppul.21311","article-title":"Pulmonary outcome prediction (POP) tools for cystic fibrosis patients","volume":"45","author":"VanDevanter","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1900224","DOI":"10.1183\/13993003.00224-2019","article-title":"Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis","volume":"54","author":"Stanojevic","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_12","unstructured":"(2024, July 25). Kaftrio\u2014A Characteristic of Product. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200821148808\/anx_148808_pl.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S1569-1993(21)01968-8","article-title":"545: Real-world experience of tezacaftor\/ivacaftor\/elexacaftor at a UK adult CF center","volume":"20","author":"Gor","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(23)00245-X","article-title":"WS10.05 Reduction of pulmonary exacerbations in people with cystic fibrosis in Germany between 2019 and 2022","volume":"22","author":"Naehrig","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: Real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"A3962","DOI":"10.1016\/j.chest.2023.07.2584","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor in preventing cystic fibrosis exacerbation in pregnancy: A cross-over case report","volume":"164","author":"Gupta","year":"2023","journal-title":"CHEST"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S1569-1993(22)00364-2","article-title":"P031 Impact of the elexacaftor\/tezacaftor\/ivacaftor combination regimen on lung function in adults with cystic fibrosis: More than just FEV1","volume":"21","author":"Dieninghoff","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2014A comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1569-1993(21)01993-7","article-title":"570: Baseline lung disease before starting elexacaftor\/tezacaftor\/ivacaftor may predict treatment response","volume":"20","author":"Holliday","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S1569-1993(21)01986-X","article-title":"563: Real-life initiation of elexacaftor\/ivacaftor\/tezacaftor in cystic fibrosis patients with severe lung disease","volume":"20","author":"Kos","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(23)00427-7","article-title":"P052 Efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with normal\/near normal FEV1 (\u226570%)","volume":"22","author":"Dagan","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(22)00858-X","article-title":"167 Two-year respiratory culture and pulmonary function outcomes in patients on elexacaftor\/tezacaftor\/ivacaftor","volume":"21","author":"Holliday","year":"2022","journal-title":"J. Cyst. Fibros."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:30Z","timestamp":1760110050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":23,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13154491"],"URL":"https:\/\/doi.org\/10.3390\/jcm13154491","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}